OpenURL Connection Search

Select item for more details and to access through your institution.

The impact of pseudomembrane formation on the outcome of Clostridium difficile-associated disease.
Published in:
Infection, 2013, v. 41, n. 5, p. 969, doi. 10.1007/s15010-013-0473-4
By:
- Berdichevski, T.;
- Keller, N.;
- Rahav, G.;
- Bar-Meir, S.;
- Eliakim, R.;
- Ben-Horin, S.
Publication type:
Article
Soluble Syndecan-1: A Novel Biomarker of Small Bowel Mucosal Damage in Children with Celiac Disease.
Published in:
2017
By:
- Yablecovitch, D.;
- Oren, A.;
- Ben-Horin, S.;
- Fudim, E.;
- Eliakim, R.;
- Saker, T.;
- Konikoff, F.;
- Kopylov, U.;
- Matthias, T.;
- Lerner, A.;
- Konikoff, F M
Publication type:
journal article
Editorial: antigenic response to CT‐P13 and infliximab originator in IBD shows similar epitope recognition—evidence from basic science supports safe switching to biosimilars. Authors’ reply.
Published in:
2018
By:
- Goncalves, J.;
- Magro, F.;
- Danese, S.;
- Lakatos, P. L.;
- Ben‐Horin, S.
Publication type:
Editorial
Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti‐tumour necrosis factor.
Published in:
Alimentary Pharmacology & Therapeutics, 2018, v. 47, n. 8, p. 1117, doi. 10.1111/apt.14567
By:
- Ben‐Horin, S.;
- Ungar, B.;
- Kopylov, U.;
- Lahat, A.;
- Yavzori, M.;
- Fudim, E.;
- Picard, O.;
- Peled, Y.;
- Eliakim, R.;
- Del Tedesco, E.;
- Paul, S.;
- Roblin, X.
Publication type:
Article
Editorial: restoring therapeutic infliximab drug levels in patients with loss of response—pharmacokinetics and anti‐drug antibodies as useful guidance tools.
Published in:
2018
By:
- Ben‐Horin, S.
Publication type:
Editorial
Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy.
Published in:
Alimentary Pharmacology & Therapeutics, 2018, v. 47, n. 2, p. 212, doi. 10.1111/apt.14410
By:
- Bar‐Yoseph, H.;
- Levhar, N.;
- Selinger, L.;
- Manor, U.;
- Yavzori, M.;
- Picard, O.;
- Fudim, E.;
- Kopylov, U.;
- Eliakim, R.;
- Ben‐Horin, S.;
- Chowers, Y.;
- Ungar, B.
Publication type:
Article
Letter: can addition of an immunomodulator really reverse antibody formation and loss of response in patients treated with adalimumab? Authors' reply.
Published in:
Alimentary Pharmacology & Therapeutics, 2017, v. 45, n. 5, p. 760, doi. 10.1111/apt.13932
By:
- Ben-Horin, S.;
- Ungar, B.;
- Roblin, X.
Publication type:
Article
Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab.
Published in:
Alimentary Pharmacology & Therapeutics, 2017, v. 45, n. 2, p. 276, doi. 10.1111/apt.13862
By:
- Ungar, B.;
- Kopylov, U.;
- Engel, T.;
- Yavzori, M.;
- Fudim, E.;
- Picard, O.;
- Lang, A.;
- Williet, N.;
- Paul, S.;
- Chowers, Y.;
- Bar‐Gil Shitrit, A.;
- Eliakim, R.;
- Ben‐Horin, S.;
- Roblin, X.
Publication type:
Article
Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis.
Published in:
Alimentary Pharmacology & Therapeutics, 2016, v. 43, n. 12, p. 1293, doi. 10.1111/apt.13631
By:
- Ungar, B.;
- Mazor, Y.;
- Weisshof, R.;
- Yanai, H.;
- Ron, Y.;
- Goren, I.;
- Waizbard, A.;
- Yavzori, M.;
- Fudim, E.;
- Picard, O.;
- Loebstein, R.;
- Kopylov, U.;
- Dotan, I.;
- Chowers, Y.;
- Eliakim, R.;
- Ben‐Horin, S.
Publication type:
Article
Undetectable anti-TNF drug levels in patients with long-term remission predict successful drug withdrawal.
Published in:
Alimentary Pharmacology & Therapeutics, 2015, v. 42, n. 3, p. 356, doi. 10.1111/apt.13268
By:
- Ben‐Horin, S.;
- Chowers, Y.;
- Ungar, B.;
- Kopylov, U.;
- Loebstein, R.;
- Weiss, B.;
- Eliakim, R.;
- Del Tedesco, E.;
- Paul, S.;
- Roblin, X.
Publication type:
Article
Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease.
Published in:
Alimentary Pharmacology & Therapeutics, 2014, v. 40, n. 6, p. 620, doi. 10.1111/apt.12869
By:
- Mazor, Y.;
- Almog, R.;
- Kopylov, U.;
- Ben Hur, D.;
- Blatt, A.;
- Dahan, A.;
- Waterman, M.;
- Ben‐Horin, S.;
- Chowers, Y.
Publication type:
Article
Letter: persistence of anti-infliximab antibodies after discontinuation of infliximab in patients with IBD - authors' reply.
Published in:
Alimentary Pharmacology & Therapeutics, 2012, v. 36, n. 5, p. 501, doi. 10.1111/j.1365-2036.2012.05215.x
By:
- Ben‐Horin, S.;
- Chowers, Y.
Publication type:
Article
Prior varicella zoster virus exposure in IBD patients treated by anti- TNFs and other immunomodulators: implications for serological testing and vaccination guidelines.
Published in:
Alimentary Pharmacology & Therapeutics, 2012, v. 36, n. 2, p. 145, doi. 10.1111/j.1365-2036.2012.05150.x
By:
- Kopylov, U.;
- Levin, A.;
- Mendelson, E.;
- Dovrat, S.;
- Book, M.;
- Eliakim, R.;
- Ben‐Horin, S.
Publication type:
Article
The decline of anti-drug antibody titres after discontinuation of anti- TNFs: implications for predicting re-induction outcome in IBD.
Published in:
Alimentary Pharmacology & Therapeutics, 2012, v. 35, n. 6, p. 714, doi. 10.1111/j.1365-2036.2012.04997.x
By:
- Ben‐Horin, S.;
- Mazor, Y.;
- Yanai, H.;
- Ron, Y.;
- Kopylov, U.;
- Yavzori, M.;
- Picard, O.;
- Fudim, E.;
- Maor, Y.;
- Lahat, A.;
- Coscas, D.;
- Eliakim, R.;
- Dotan, I.;
- Chowers, Y.
Publication type:
Article
Review article: loss of response to anti-TNF treatments in Crohn's disease.
Published in:
Alimentary Pharmacology & Therapeutics, 2011, v. 33, n. 9, p. 987, doi. 10.1111/j.1365-2036.2011.04612.x
By:
- Ben‐Horin, S.;
- Chowers, Y.
Publication type:
Article
The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab.
Published in:
Alimentary Pharmacology & Therapeutics, 2011, v. 33, n. 3, p. 349, doi. 10.1111/j.1365-2036.2010.04523.x
By:
- Kopylov, U.;
- Mantzaris, G. J.;
- Katsanos, K. H.;
- Reenaers, C.;
- Ellul, P.;
- Rahier, J. F.;
- Israeli, E.;
- Lakatos, P. L.;
- Fiorino, G.;
- Cesarini, M.;
- Tsianos, E. V.;
- Louis, E.;
- Ben‐Horin, S.
Publication type:
Article
Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease.
Published in:
Journal of Crohn's & Colitis, 2014, v. 8, n. 6, p. 443, doi. 10.1016/j.crohns.2013.12.013
By:
- Rahier, J.F.;
- Magro, F.;
- Abreu, C.;
- Armuzzi, A.;
- Ben-Horin, S.;
- Chowers, Y.;
- Cottone, M.;
- de Ridder, L.;
- Doherty, G.;
- Ehehalt, R.;
- Esteve, M.;
- Katsanos, K.;
- Lees, C.W.;
- MacMahon, E.;
- Moreels, T.;
- Reinisch, W.;
- Tilg, H.;
- Tremblay, L.;
- Veereman-Wauters, G.;
- Viget, N.
Publication type:
Article
Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response.
Published in:
Inflammatory Bowel Disease Monitor, 2013, v. 13, n. 3, p. 118
By:
- Ben-Horin, S.
Publication type:
Article

Found: 18